Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · December 03, 2018

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy in Patients With Advanced Unresectable Melanoma

JAMA Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Dermatology
Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
JAMA Dermatol 2018 Nov 21;[EPub Ahead of Print], AR Almutairi, NS Alkhatib, M Oh, C Curiel-Lewandrowski, HM Babiker, LD Cranmer, A McBride, I Abraham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading